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Abstract
Thrombolysis by intravenous recombinant tissue plasminogen activator (rt-PA) is an effec-
tive therapy in acute ischemic stroke (AIS). Thrombin generation test (TGT) is a global
hemostasis test providing information about the speed and amount of generated thrombin in
plasma. Here we aimed to find out whether results of this test before the initiation of throm-
bolysis might predict outcomes. Study population included 120 consecutive AIS patients, all
within 4.5 hours of their symptom onset, who underwent thrombolysis by rt-PA. Blood sam-
ples were collected from all patients upon admission and TGT was performed using platelet
poor plasma. Clinical data of patients including the NIHSS were registered at admission,
day 1 and 7 after therapy. The ASPECT score was assessed using CT images taken before
and 24 hours after thrombolysis. Long-term functional outcome was defined 3 months after
the event by the modified Rankin Scale. Endogenous Thrombin Potential (ETP) and Peak
Thrombin were significantly lower in patients with cardioembolic IS. Symptomatic intracra-
nial hemorrhage (SICH) was found in 6 patients and was significantly associated with low
ETP and Peak Thrombin levels. A multiple logistic regression model revealed that an ETP
result in the lower quartile is an independent predictor of mortality within the first two weeks
(OR: 6.03; 95%CI: 1.2–30.16, p<0.05) and three months after the event (OR: 5.28; 95%CI:
1.27–21.86, p<0.05). Low levels of ETP and Peak Thrombin parameters increase the risk of
therapy associated SICH. A low ETP result is an independent predictor of short- and long-
term mortality following thrombolysis.
Introduction
Early intravenous administration of recombinant tissue plasminogen activator (rt-PA) has
been proven to be an effective therapy for acute ischemic stroke (AIS) [1,2]. Although those
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eligible for this therapy are carefully selected, about 6% of patients undergoing thrombolysis
develop potentially fatal intracranial hemorrhage as a side effect [3]. On the other hand, in a
subset of patients thrombolysis is inefficient and due to the failure of recanalization no clinical
improvement is observed [4]. Today, these events cannot be foreseen at the initiation of the
therapy and only few conventional risk factors (e.g. age, stroke severity, hyperglycemia, etc.)
may be considered to predict outcomes. In theory, the lysis of the clot is likely to depend on
factors influencing clot structure. Given the complexity of the hemostasis system, which
involves several interrelated procoagulant and anticoagulant pathways, measuring the levels of
individual proteins might have limited utility in the prediction of therapeutic outcomes.
Thrombin generation test (TGT) is a global hemostasis test providing information about the
speed and amount of generated thrombin in plasma [5]. Here we aimed to find out whether
results of this test before the initiation of therapy might predict outcomes after thrombolysis.
Materials and methods
Study population
Patients were enrolled between March 2011 and January 2013 in a single Stroke Center
(Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary).
Study population included consecutive acute ischemic stroke patients admitted within 4.5
hours of their symptom onset undergoing intravenous (i.v.) thrombolytic therapy according to
the European Stroke Organization guidelines [6] using recombinant tissue plasminogen acti-
vator (rt-PA, Alteplase, Boehringer Ingelheim, Germany). Patients who were on anticoagulant
therapy at admission were excluded from the study population. All enrolled patients or their
relatives had been informed about the study and gave written informed consent. The study
was approved by the Ethics Committee of University of Debrecen, Debrecen, Hungary.
Blood sampling and routine laboratory measurements
Peripheral blood samples were drawn from patients on hospital admission into vacutainer
tubes (tubes with no anticoagulant for routine clinical chemistry tests, tubes anticoagulated
with K3-EDTA for complete blood count and tubes containing 0.105 M sodium citrate for rou-
tine hemostasis tests, Becton Dickinson, Franklin Lakes, NJ). Plasma from tubes containing
sodium citrate, theophylline, adenosine and dipyridamole (Vacuette CTAD Tubes, Greiner
Bio-One, Vienna, Austria) was separated by centrifugation at 1220 g for 15 min, room temper-
ature and samples were stored at -70˚C until the determination of thrombin generation.
Serum ions, glucose levels, basic kidney function tests, liver function tests, lipid profile and
high sensitivity C-reactive protein (CRP) were determined by conventional methods (Roche
Diagnostics, USA). Routine hemostasis tests were measured immediately after plasma separa-
tion (Siemens Healthcare Diagnostics, Marburg, Germany).
Thrombin generation test
Thrombin generation test was performed as described previously using the Thrombinoscope
CAT (Calibrated Automated Thrombogram, Maastricht, The Netherlands) assay according to
the manufacturer’s instructions (Diagnostica Stago, Asnières, France) [7,8]. Briefly, 80 microli-
ters of plasma was incubated with 20 μL PPP-Reagent™ (containing 5 pM recombinant tissue
factor and 4 μM phospholipids) for 10 minutes in round-bottomed 96-well black microplates.
For each sample, a calibrator (Thrombin Calibrator™) was run in parallel in order to correct
the fluorescence signal for substrate consumption and plasma color variability. Thrombin gen-
eration was initiated by the addition of 20 μL of FluCa-Kit™ (a mixture of Fluorogenic substrate
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and Fluo-Buffer containing CaCl2). All samples were run in duplicates. Fluorescence was
detected by a Fluoroskan Ascent1 fluorimeter (Thermo Fischer Scientific, Waltham, MA) and
the thrombin generation curves were analysed by the Thrombinoscope software (Thrombino-
scope BV, Maastricht, The Netherlands). Thrombin generation curves were characterised by
the following parameters (calculated and presented by the Thrombinoscope software): 1/Lag-
time: the moment at which thrombin generation starts, 2/Endogenous Thrombin Potential
(ETP): the area under the curve, 3/Peak Thrombin: the highest thrombin concentration,
4/Time to Peak: the time until the Peak Thrombin, 5/Start Tail: the time to end-point of
thrombin generation and 6/Velocity Index: the slope of the curve between the beginning of
thrombin generation and the Time to Peak parameter.
Clinical data
For each patient the time of symptom onset, demographic and clinical characteristics (smok-
ing status, previous medication, neurological status) were recorded upon admission. Neuro-
logical deficit of patients was determined by the National Institute of Health Stroke Scale
(NIHSS) [9] on admission (before thrombolysis) and at 2 h, 24 h and 7 days after thrombolytic
therapy. Unfavourable short-term functional outcome was defined as an increase in the
NIHSS by at least 4 points by day 7. Upon admission, all patients underwent computer tomog-
raphy brain scan (CT) and CT angiography (CTA) to ensure the diagnosis of acute ischemic
stroke. Stroke etiology was classified according to the Trial of Org 10172 in Acute Stroke Treat-
ment (TOAST) criteria [10]. A control CT was performed for every patient 24 hours after rt-
PA infusion. Hemorrhagic events on the control CT scan were classified as symptomatic
(SICH) or asymptomatic intracranial hemorrhage (aSICH) according to the European Coop-
erative Acute Stroke Study (ECASS) II criteria [11]. CT images taken before and 24 hours after
the therapy were analysed by 4 different investigators and the Alberta Stroke Program Early
CT Scores (ASPECTS) were calculated [12]. Each patient was evaluated for the following car-
diovascular risk factors: arterial hypertension, atrial fibrillation, hyperlipidemia and diabetes
mellitus based on the use of medications or previous history. Patients were followed-up and
long-term functional outcomes were determined at 3 months after the stroke event using the
modified Rankin Scale (mRS). Unfavourable long-term outcome was defined as a mRS score
greater than 1.
Statistical analysis
Evaluation of the results was performed according to: stroke etiology, stroke severity (classifi-
cation based on the baseline NIHSS: 0–5, 6–10, 11–15,>15), the presence of intracranial hem-
orrhage after thrombolysis treatment, short-term and long-term functional outcomes and
mortality.
Normality of the data was evaluated by the Shapiro-Wilk test. ANOVA using the Bonfer-
roni correction or Kruskal-Wallis test using the Dunn’s post test were applied for multiple
comparisons. In all two-group analyses unpaired t-test or in case of non-parametric data
Mann-Whitney U test was used. Pearson’s or Spearman’s correlation coefficient was used to
determine the strength of correlation between parameters of the thrombin generation test and
other continuous variables. A backward multiple logistic regression model was used to deter-
mine factors that are independent predictors of hemorrhagic transformation or death after
thrombolysis. Variables were selected for entry into the multivariate model based on the results
of univariate and correlation analyses, previous literature and other methodological principles
(dichotomized variables wherever possible). Results of the logistic regression analysis were
expressed as odds ratio (OR) and 95% confidence interval (CI). A p value of<0.05 was
Thrombin generation in stroke
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considered statistically significant. Statistical analysis was performed using Stata 12 (Stata
Corp LP, Texas, USA) and GraphPad Prism 5.0 (GraphPad Prism Inc., La Jolla, CA, USA)
softwares.
Results
A total of 120 consecutive AIS patients receiving i.v. thrombolysis were included in the study.
Baseline demographic characteristics of patients and stroke characteristics are shown in Tables
1 and 2. In case of 6 patients i.v. thrombolytic therapy was supplemented with intraarterial
thrombolysis according to the standard protocol; the final dose of rtPA and the duration of
thrombolysis was not significantly different in case of these patients. Median age was 69.0
(IQR: 59.0–79.0) years, 59.2% were men. Median NIHSS on admission was 8 (IQR: 5–14).
Median time-to-treatment with rt-PA was 159 min (IQR: 125–180 min). According to the
TOAST criteria, a major fraction of the patients had atherothrombotic stroke (large-artery ath-
erosclerosis: 38.3%, small-vessel occlusion: 11.7%). A favourable short-term outcome was
Table 1. Baseline characteristics of patients.
Characteristic Values
n 120
Age (years), median (IQR) 69.0 (59.0–79.0)
Male, n (%) 71 (59.2)
Cerebrovascular risk factors, n (%)
Arterial hypertension 91 (76.0)
Atrial fibrillation 28 (23.3)
Hyperlipidaemia 75 (62.5)
Diabetes mellitus 36 (30.0)
Previous stroke 37 (30.8)
Smoking, n (%)
Non-smoker 63 (52.5)
Previous smoker 15 (12.5)
Active smoker 30 (25.0)
Undetermined 12 (10.0)
Serum glucose (mmol/L), median (IQR) 6.4 (5.5–7.8)
C-reactive protein (mg/L), median (IQR) 3.1 (1.5–5.7)
INR, median (IQR) 1.0 (0.9–1.0)
Current drug use, n (%)
Antihypertensive therapy 84 (70.0)
Antiplatelet drug* 52 (43.3)
Lipid-lowering therapy 34 (28.3)
Undetermined 8 (6.7)
Thrombin generation parameters, median (IQR)
Lagtime (min) 3.7 (3.0–4.2)
ETP (nM x min) 1482.0 (1266.0–1785.0)
Peak Thrombin (nM) 258.0 (204.7–315.3)
Time to Peak (min) 7.2 (6.3–8.4)
StartTail (min) 23.7 (21.8–25.4)
Velocity Index (nM/min) 73.3 (50.2–101.9)
IQR: interquartile range, INR: international normalized ratio, ETP: Endogenous Thrombin Potential.
*Aspirin or P2Y12 inhibitor treatment or both.
https://doi.org/10.1371/journal.pone.0180477.t001
Thrombin generation in stroke
PLOS ONE | https://doi.org/10.1371/journal.pone.0180477 July 10, 2017 4 / 13
observed in 40% of the patients. Unfavourable short-term and long-term outcome was found
in 14.2% and 46.7% of all cases, respectively. Mortality by day 7, day 14 and by the end of the
3rd month was 4.2%, 12.5% and 21.7%, respectively. Mortality rates were not different accord-
ing to the etiology of the stroke (data not shown). Hemorrhagic complications were detected
Table 2. Stroke characteristics.
Characteristic Values
Time to treatment (min) with rt-PA, median (IQR) 159.0 (125.0–180.0)
Duration of thrombolysis treatment (min), median (IQR) 60.0 (60.0–64.0)
Dose of rt-PA, (mg±SD)
Intravenous rt-PA 67.6±15.5
Bridging (combined intravenous and intraarterial) 68.0±12.5
Stroke etiology (TOAST), n (%)
Large-artery atherosclerosis 46 (38.3)
Small-vessel occlusion 14 (11.7)
Cardioembolic 23 (19.2)
Other/undetermined 37 (30.8)
Stroke severity on admission, n (%)
NIHSS 0–5 35 (29.2)
NIHSS 6–10 44 (36.7)
NIHSS 11–15 18 (15.0)
NIHSS >15 21 (17.5)
Undetermined 2 (1.6)
Short-term functional outcome, n (%)
Favourable 48 (40.0)
No change 43 (35.8)
Unfavourable 17 (14.2)
Death 5 (4.2)
Undetermined 7 (5.8)
Haemorrhagic transformation (ECASS II), n (%) 13 (10.8)
aSICH 7 (5.8)
SICH 6 (5.0)
Mortality by day 7, n (%)
Survival 115 (95.8)
Death 5 (4.2)
Mortality by day 14, n (%)
Survival 105 (87.5)
Death 15 (12.5)
Long-term functional outcome at 3months, n (%)
mRS 0–1 41 (34.2)
mRS 2–5 30 (25.0)
mRS 6 (death) 26 (21.7)
Undetermined 23 (19.1)
Imaging data (median, total range)
ASPECTS on admission 10.0 (7.0–10.0)
ASPECTS at 24 h 9.0 (0.0–10.0)
rt-PA: recombinant tissue type plasminogen activator, TOAST: Trial of Org 10172 in
Acute Stroke Treatment, NIHSS: National Institute of Health Stroke Scale, ECASS II: European Cooperative
Acute Stroke Study II, aSICH: asymptomatic intracranial hemorrhage, SICH: symptomatic intracranial
hemorrhage, mRS: modified Rankin Scale, ASPECTS: Alberta Stroke Program Early CT Score.
https://doi.org/10.1371/journal.pone.0180477.t002
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in case of 13 patients, among which 6 had SICH (5% of total patient population). One patient
had died due to intracranial hemorrhagic complication on the 6th day of therapy. The occur-
rence of hemorrhagic complications was not significantly different in strokes of atherothrom-
botic origin as compared to cardioembolic strokes.
Thrombin generation as a predictor of thrombolysis outcome
The median and IQR results of the thrombin generation parameters for the whole patient pop-
ulation are shown in Table 1. Among the baseline characteristics of the patient population,
correlation and univariate analysis revealed no association with any thrombin generation
parameters except for a weak negative association between age and the ETP and Time to Peak
parameters (Spearman r = -0.25, p = 0.006 and r = -0.20, p = 0.02, respectively). No association
was found between the results of any parameters of the thrombin generation test and the
ASPECT scores on admission/24 hours after therapy and the time between symptom onset to
blood sampling (data not shown). ETP and Peak Thrombin parameters were significantly
lower in case of cardioembolic stroke as compared to that of atherothrombotic origin (Fig 1A).
Other thrombin generation parameters were not associated with the subtype of stroke. Time
to Peak was significantly shorter in case of more severe stroke indicating that peak thrombin
generation occurs faster in these patients (Fig 1B). No association was found between the
severity of the stroke and other thrombin generation parameters. ETP and Peak Thrombin
parameters were significantly lower in those patients who suffered SICH as compared to the
patients with no recorded bleeding complications or with aSICH (Fig 2). A multiple logistic
regression analysis including age, sex, CRP, smoking, antiplatelet drug use and NIHSS on
admission revealed that an ETP result under the lowest quartile (<1265.9 nM x min) signifi-
cantly increased the risk of therapy-associated SICH (OR: 17.54, 95%CI: 1.45–212.72, p<0.05).
Similarly, a Peak Thrombin result under the lowest quartile (<204.7 nM) on admission was an
independent predictor of therapy-associated SICH (OR: 15.12, 95%CI: 1.38–166.02, p<0.05).
Low ETP and Peak Thrombin parameters were significantly associated with short-term
mortality, while none of the thrombin generation parameters showed significant differences in
other categories of short-term functional outcomes (favourable, no-change, unfavourable)
(data not shown). A significantly lower ETP but not Peak Thrombin result was found in those
patients who died by the end of the 3rd month (mRS = 6) as compared to those with better out-
comes (Table 3). On the other hand, as compared to patients with better functional outcomes
at 3 months (mRS 0–1), ETP was not significantly lower in those patients who had worse func-
tional outcomes (mRS 2–5) but survived by the end of the 3rd month (Table 3). In a stepwise
backwards regression analysis (performed with age, sex, CRP, smoking, antiplatelet drug use
and NIHSS on admission) only age, lowest quartile ETP and lowest quartile Peak Thrombin
results remained in the model as independent risk factors for mortality by day 14 (Table 4).
Using the same model to test potential risk factors independently associated with mortality by
the end of the 3rd month, an ETP result in the lowest quartile, age>79 years and NIHSS>15
were found to be significant predictors, revealing odds ratios of 5.28 (95%CI:1.27–21.86,
p = 0.022), 8.96 (95%CI:1.75–45.93, p = 0.009) and 5.93 (95%CI:1.31–26.80, p = 0.021), respec-
tively (Table 4).
Discussion
In this single-center study of 120 AIS patients treated with i.v. t-PA, we show for the first time
that results of the thrombin generation test obtained before the thrombolytic treatment could
be a useful marker to predict short- and long-term outcomes. Thrombin is a major effector of
the coagulation process and it is an important regulator of thrombus growth and structure. In
Thrombin generation in stroke
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Fig 1. The association of thrombin generation parameters with the etiology (A) and the severity (B) of
stroke. Box and whisker plots indicate median, interquartile range and total range. Statistical significance was
assessed by Mann-Whitney U test (A) and Kruskal-Wallis and Dunn’s Multiple Comparison Test (B).
*Statistically significant (p<0.05), ns: non-significant. ETP: Endogenous Thrombin Potential, NIHSS: National
Institutes of Health Stroke Scale.
https://doi.org/10.1371/journal.pone.0180477.g001
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our study, a decrease in the total amount of thrombin generated in the patients’ plasma was
found to be an independent predictor of mortality. In a multiple logistic regression analysis for
mortality, an ETP result under the lowest quartile showed an OR: 6.03 (95%CI: 1.2–30.15,
p<0.05) and OR: 5.28 (95%CI: 1.27–21.86, p<0.05) for mortality by the end of the 2nd week
and by the end of the 3rd month after the event, respectively. The relatively low potential of
thrombin generation in these plasma samples most likely reflects an intense prior or ongoing
activation of coagulation leading to a consumption of coagulation factors which are normally
required for thrombin generation to take place. This is in line with previous findings that in
patients with coronary heart disease, a trend of lower ETP/Peak Thrombin was found in those
with recurrent thrombotic events [13]. The immense activation of coagulation that is present
in the first hours of AIS might not be easily traced in its complexity by other methods. In fact,
the NIHSS, which is commonly used to assess the severity of the stroke, might not reflect the
size and the structural features of the forming thrombus, as the symptoms of the patient are
largely dependent on the location of the blood clot. In line with this hypothesis, no association
was found between the NIHSS of the patients on admission and the total or maximal amount
of thrombin (ETP or Peak Thrombin parameters) generated in their plasma samples. Only
Time to Peak was significantly shorter in case of more severe stroke indicating that peak
thrombin generation occurs faster in these patients. Our results suggest that in a fraction of the
patient population eligible for thrombolysis treatment, the risk for mortality is higher, and it is
associated with low thrombin generation potential. The TG method was able to differentiate
between patients at high risk and low risk for mortality, however, we found no differences in
the TGT results between those who survived with different outcomes as classified based on the
changes in the NIHSS or the mRS score.
We also show here that besides the increased risk for mortality due to ongoing coagulation,
therapy-associated bleeding risk is also higher in the patients with low TG potential. A multiple
logistic regression analysis including age, sex, CRP, smoking, antiplatelet drug use and NIHSS
on admission revealed that an ETP or a Peak Thrombin in the lowest quartile are independent
predictors of therapy-associated SICH (OR: 17.54, 95%CI: 1.45–212.72, p<0.05 and OR: 15.12,
Fig 2. The association of (A) Endogenous Thrombin Potential (ETP) and (B) Peak Thrombin levels with therapy-associated
intracranial hemorrhage. Box and whisker plots indicate median, interquartile range and total range. Statistical significance was
assessed by Kruskal-Wallis and Dunn’s Multiple Comparison Test. *Statistically significant (p<0.05). ETP: Endogenous Thrombin
Potential, aSICH: asymptomatic intracranial haemorrhage, SICH: symptomatic intracranial haemorrhage.
https://doi.org/10.1371/journal.pone.0180477.g002
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Table 3. Characteristics of the patients on admission according to clinical outcome by the end of the 3rd month.
Variable mRS 0–1
(n = 42)
mRS 2–5
(n = 30)
mRS 6
(n = 26)
Age, years 68.0 (58.0–79.0) 66.0 (58.0–77.0) 79.5 (70.0–85.0)*#†
Male 29 (69.1) 15 (50.0) 14 (53.9)
Arterial hypertension 33 (78.6) 23 (76.7) 19 (73.1)
Atrial fibrillation 11 (26.2) 4 (13.3) 9 (34.6)
Hyperlipidaemia 27 (64.3) 21 (70.0) 12 (46.2)
Diabetes mellitus 9 (21.4) 12 (40.0) 9 (34.6)
Previous stroke 12 (28.6) 12 (41.4) 7 (28.0)
Active smoker 6 (16.2) 12 (41.4)* 6 (26.1)
Serum glucose (mmol/L) 6.5 (6.0–7.6) 6.4 (5.6–8.1) 6.3 (5.5–7.5)
C-reactive protein (mg/L) 1.8 (0.8–3.6) 4.1 (1.7–5.8)* 4.4 (1.9–6.6)*†
Antihypertensive therapy 27 (73.0) 22 (75.9) 15 (62.5)
Antiplatelet therapy 18 (43.9) 14 (46.7) 14 (56.0)
Lagtime (min) 3.7 (2.8–4.3) 3.5 (2.8–4.0) 3.3 (3.2–3.8)
ETP (nM x min) 1472.6 (1291.9–1746.0) 1512.8 (1319.0–1797.1) 1275.1 (1135.3–1552.0)*#†
Peak Thrombin (nM) 268.5 ± 88.9 277.2 ± 90.7 226.8 ± 75.0
Time to Peak (min) 7.3 (6.3–8.3) 6.7 (5.7–7.7) 6.8 (6.2–8.5)
Start Tail (min) 23.4 (21.5–25.3) 23.3 (21.8–25.3) 22.9 (21.5–25.0)
Velocity Index (nM/min) 71.5 (50.6–97.2) 86.9 (60.1–140.3) 71.0 (46.2–84.3)
Time to treatment (min) with rt-PA 169.0 (120.5–181.0) 148.5 (125.0–180.0) 152.0 (130.0–176.0)
Cardioembolic stroke 9 (29.0) 5 (20.8) 6 (31.6)
NIHSS on admission 5.0 (4.0–9.0) 9.0 (6.0–15.0)* 16.0 (8.0–21.0)*†
ASPECTS on admission 10.0 (9.0–10.0) 9.5 (9.0–10.0) 10.0 (9.0–10.0)
Values are given as mean ± SD or median (IQR) or number (percentage). mRS: modified Rankin Scale, ETP: Endogenous Thrombin Potential, rt-PA:
recombinant tissue type plasminogen activator, NIHSS: National Institutes of Health Stroke Scale, ASPECTS: Alberta Stroke Program Early CT Score.
*p<0.05 as compared to mRS 0–1,
#p<0.05 as compared to mRS 2–5,
†p<0.05 for all-group comparison (ANOVA or Kruskal-Wallis).
https://doi.org/10.1371/journal.pone.0180477.t003
Table 4. Multiple logistic regression analysis for mortality.
Odds ratio 95% Confidence Interval P value
Mortality by day 14
ETP under 1265.9 nM x min* 6.03 1.20–30.16 0.029
Peak Thrombin under 204.7 nM* 6.81 1.09–42.65 0.040
Age>79 years 6.66 1.12–39.51 0.037
Mortality by the end of the 3rd month
ETP under 1265.9 nM x min* 5.28 1.27–21.86 0.022
Age>79 years 8.96 1.75–45.93 0.009
NIHSS >15 5.93 1.31–26.80 0.021
Backward multiple logistic regression model included age, sex, CRP, smoking, antiplatelet drug use and
NIHSS on admission. NIHSS: National Institute of Health Stroke Scale, ETP: Endogenous Thrombin
Potential.
*Under the lowest quartile.
https://doi.org/10.1371/journal.pone.0180477.t004
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95%CI: 1.38–166.02, p<0.05, respectively). The prior over-activation of coagulation and the
resulting decrease of the thrombin generation potential, possibly due to consumption, might
result in the therapy-associated bleeding tendency in these patients. In an earlier study includ-
ing 114 AIS patients undergoing i.v. thrombolysis, baseline parameters of selected coagulation
and fibrinolysis markers did not yield to any significant association with SICH [14]. This result
suggests the advantage of TGT over single factor determinations when testing the levels of
coagulation markers as predictors of bleeding. TGT as a global test incorporates the multiple
procoagulant and anticoagulant pathways in its final result, therefore it more likely represents
the situation occurring in the in vivo environment. Recently, TGT has been used to predict
bleeding tendency in various clinical conditions. In hemophiliac patients and in hemophiliacs
with inhibitors, its usefulness has been proved, and it has been a matter of debate whether the
TGT might describe the risk of bleeding better than traditional tests [15–17]. TGT, when per-
formed preoperatively, was found to be useful in providing information predictive for blood
loss after cardiac surgery [18].
Among the baseline characteristics of our patient population no association was found with
any parameters of the TGT except for a weak negative association between ETP and Time to
Peak parameter with age. Similar association between the Time to Peak parameter and age has
been described in healthy individuals [19], and lower mean ETP results were obtained in indi-
viduals >75 years of age in a large cohort study including elderly subjects [20]. In our study
significantly lower ETP and Peak Thrombin parameters were found in case of cardioembolic
stroke vs. that of atherothrombotic origin. This result at first seems to contradict the results
published by Rooth et al [21], who found similar thrombin generation capacity in patients
with non-cardioembolic and cardioembolic strokes. However, in that study blood sampling
and thrombin generation was performed within the first two weeks after the stroke event,
while in our case all patients were sampled within 4.5 hours after the first symptoms of stroke.
Our results are in line with those published by Gissel et al, who found that using a mathemati-
cal model to calculate thrombin generation (using plasma levels of clotting factors measured
from patients sampled within 24 hours of symptom onset), all stroke sub-types except for car-
dioembolic had increased total thrombin produced [22]. Atherothrombotic strokes have dif-
ferent hemostatic risk factors than those of cardioembolic origin: it has been shown that the
hemostatic profile is different and is more likely to be thrombogenic in atherothrombotic
strokes as compared to cardioembolic strokes, which might explain our findings [23].
Our study has some limitations. First, the number of patients with symptomatic hemor-
rhage was small, which was obviously due to the fact that it was a single-site study with a lim-
ited number of eligible patients per year. However, as thrombin generation measurements are
highly sensitive to pre-analytical variables, including the method of blood collection, plasma
isolation and sample storage conditions [24], up to the point where these variables may signifi-
cantly influence assay results [25], the study was designed to be single-centered in order to
assure unified sample handling. As results were significantly different in case of patients with
or without SICH, the possibility of a type II error should not be considered in our case. Second,
in theory, some patients might have had inherited thrombophilia risk factors influencing TG
results and this was not tested. However, as the youngest patient having stroke in this cohort
was 59 years old and all patients had negative history for venous thromboembolism, the occur-
rence of major thrombophilia risk factors influencing the results seemed rather low in this
cohort and did not seem worthwhile to perform such an exhaustive test panel to rule out this
possibility. Third, thrombin generation test has a number of limitations. The assay is still not
standardized enough for broad clinical use and there is a lack of reference range for specific
conditions, including the condition we have used in this study [26]. It was not our aim in this
study to develop a reference range tested on healthy individuals and therefore no such
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population was enrolled here. Although standardization of the TGT is far from being com-
pleted, optimal experimental conditions have been described previously, which were followed
by us in this study [26, 27]. This includes, among others, the use of a standardized thrombin
calibrator, which allows the quantitative expression of thrombin, the use of the Thrombogram
software, which can reliably describe the distinct phases of thrombin generation, and the prac-
tice that all samples were run in duplicates.
Conclusions
We have shown for the first time that the TGT might be a useful tool to predict outcomes in
AIS patients undergoing thrombolysis. Patients with low thrombin generation potential (low
ETP parameter) on admission were found to have an increased risk of worse therapeutic out-
comes including therapy-associated symptomatic intracranial bleeding or death. Prospective
studies are needed in the future in order to test whether these selected patients might benefit
from altered and/or supplemented therapeutic profiles.
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